thanks
thank you gentlemen
really got upside down here with a sizeable amount of shares. i want to hold on. but, not sure where the bottom is. its feeling like the shorts own this thing. thinking about exiting yet my better sense is telling me to wait it out.
they probably bonusued themselved millions of the 40mm while shareholders are getting murdered.
i like you hope as we get walked down to 4.
now is some agressive insider buying. i'm running out of patience.
ya right .... market is up 200 pts last 2 days and we continue to slide down to 4.
we've already had some major catalysts.... Options expiration ? i don't think so volume is light. i just don't get it. unless the warrants issue is just to much overhead supply. shorts have to believe we're near a bottom. too many other great short opps in the market. after 20 yrs of trading / investing. i'm dumbfounded here and super disapointed. patience is running thin...
what we need is insiders to step in with a huge buy to show some confidence its the least they could do after all these fricken warrants.,
Thus I say: ALXA is a great investment and it could be one of the most undervalued stocks in the market.
they laid out thier cases very cleanly. now , lets start seeing some tracting....oh ya... upgrades would be nice or some new converage from tier 1 shops.
thanks cancunfish for the DD. I wil cross reference with my mock cap table. what are the tea leaves indicating to you on pps basis near term. do you think some of the short shares covered ?
at .50
the above is from feb , 2012. you can google it.
Alexza Pharmaceuticals, Inc. announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock. The common stock and warrants will be issued separately, but will be sold in combination in the offering, with a warrant to purchase one share of common stock for each share of common stock sold. The price to the public for each share and related warrant is USD0.50 , for an aggregate offering amount of approximately USD22 million . The net proceeds to Alexza, after underwriting discounts and commissions and other offering expenses, and assuming the warrants are not exercised, are expected to be approximately USD20.4 million . Alexza plans to use the net proceeds from the sale of securities primarily for general corporate purposes, including regulatory, clinical trial, research and development, general and administrative and manufacturing expenses
my only concern now is the warrants with the $5.00 strike price. i read there was 4.4 mm but with some additional due diligence came across some data suggesting thier was more warrants issued on a previous offering bringing the total to 11mm. Thus, it will be very hard to climb past $5.00pps with that supply. remember warrant holders are basically put buyers thus thier short. not sure how this will work itself out. it got me concerned.
new drug in production, no cap raise , ramping up for getting to market in US and EU. smaller payout to acquiring co / cap at 10%, reduced burn.... i thought it was a all positive . i think we start the climb to 8.
getting ready for a Q3 rollout / EU partner ready to roll. new drug in trials. plenty of cash / no offering slated. should be Ebitda profitable by end of the year. we should start moving up. bottom is in.
teva has the rights to exchange 25mm loan if used to warrants. no biggie. in regards to 195 thats all ALXA... loss was derived in part from 10mm payment thus its kinda of a quality problem. i suspect TEVA buys out ALXA in the next 2 years.
they have not even gone to market yet. earning where from a license deal